COGT
Cogent BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Successful clinical readouts or a partnership deal could drive accelerated adoption of the drug candidate and multiple expansion; bull target assumes ~50% upside vs anchor with positive news.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +12.0.
What can break
Clinical failure or need for additional financing would depress valuation; bear target reflects substantial dilution/negative readthroughs and a large drawdown.
Momentum
79
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.50 · Bull $12.75 · Bear $5.10
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $54.25
Why
Momentum79 · Δ7d +12.0
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
79
26% active weight
Current posture
7d trendImproving
Δ7d
+12.0
Δ21d
+34.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 78.9 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$6.68B
Beta
0.45
Shares Out
170.91M
P/E (TTM) · Derived
-15.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-19.31
Rev YoY
-100.0%
EPS YoY
-5.5%
Gross Margin
-
Op Margin
-
Net Debt
-$661.97M
Current Ratio
15.14
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology